Peripheral T-cell Lymphomas

Abstract

Objective:Peripheral T-cell lymphomas (PTCLs) confer dismal prognosis and no consensus has been established on the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to its rarity and heterogeneity. The purpose was to review key points of allo-HSCT for PTCLs, including indication, times of transplantation, conditioning regimen, graft versus host disease prophylaxis, and treatment of relapse.Data Sources:A comprehensive search in PubMed and Cochrane up to February 28, 2018, with the keywords “Peripheral”, “T”, “Lymphoma”, and “Transplantation” was done.Study Selection:Relevant articles including HSCT for PTCLs were carefully reviewed.Results:Promising data have been reported from advances in transplant technology and more and more PTCLs patients with poor prognosis could benefit from allo-HSCT.Conclusion:Allo-HSCT is a useful choice for patients with refractory/relapsed PTCLs or high-risk new diagnosed PTCLs.

Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis

“…In published literature, patients with ATL who underwent allo-HSCT experienced grade 3–4 acute GVHD at rates of approximately 14% to 20% [ 17 ]. Rates of chronic GVHD for patients with PTCL who undergo allo-HSCT have been reported to be between 30 and 60%, but additional findings are limited, as PTCL has relatively low survival rates [ 18 ]. Data on the role of allo-HSCT in CTCL are also limited, and no prospective trials have been performed to date.…”

A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China

“…Autologous hematopoietic stem cell transplantation (auto-HSCT) has been exploited as consolidation both in first remission and refractory/relapsed settings [9–12] . Allogeneic HSCT (allo-HSCT) is mainly tried in relapsed and refractory patients and shows promising results [13–15] . Key questions about the relative efficacy of auto-HSCT vs .…”

“…[9][10][11][12] Allogeneic HSCT (allo-HSCT) is mainly tried in relapsed and refractory patients and shows promising results. [13][14][15] Key questions about the relative efficacy of auto-HSCT vs. allo-HSCT, identification of their optimal candidates, and optimal HSCT timing remain uncertain. Our study provides real-world data about auto-HSCT and allo-HSCT for PTCL in China.…”

Increased risk of cardio-cerebrovascular disease after hematopoietic cell transplantation in patients with previous history

“…Hematopoietic cell transplantation (HCT) is an established treatment for hematologic malignancies. [1][2][3] The safety of HCT has greatly improved over the past decades, with its tolerance being attributed to the availability of improved supportive care practices and widespread adoption of the practice of careful evaluation of comorbidities before the transplantation. [4] Cardio-cerebrovascular comorbidities have been well identified as risk factors for non-relapse mortality (NRM) following transplantation, their presence accounting for a score of 1 in the HCT-specific comorbidity index (HCT-CI).…”

“…Hematopoietic cell transplantation (HCT) is an established treatment for hematologic malignancies [1–3] . The safety of HCT has greatly improved over the past decades, with its tolerance being attributed to the availability of improved supportive care practices and widespread adoption of the practice of careful evaluation of comorbidities before the transplantation [4] .…”